Last reviewed · How we verify
GMDTC for injection
GMDTC for injection is a Small molecule drug developed by Guangdong Jianersheng Pharmaceutical Technology Co., Ltd.. It is currently in Phase 2 development. Also known as: GMDTC Group.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | GMDTC for injection |
|---|---|
| Also known as | GMDTC Group |
| Sponsor | Guangdong Jianersheng Pharmaceutical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Safety and Efficacy of GMDTC for Injection in Subjects With Elevated Cadmium Levels (PHASE2)
- Safety Study of GMDTC Injection in Participants With Excessive Cadmium (PHASE1)
- Safety Study of GMDTC Injection in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GMDTC for injection CI brief — competitive landscape report
- GMDTC for injection updates RSS · CI watch RSS
- Guangdong Jianersheng Pharmaceutical Technology Co., Ltd. portfolio CI
Frequently asked questions about GMDTC for injection
What is GMDTC for injection?
Who makes GMDTC for injection?
Is GMDTC for injection also known as anything else?
What development phase is GMDTC for injection in?
Related
- Manufacturer: Guangdong Jianersheng Pharmaceutical Technology Co., Ltd. — full pipeline
- Also known as: GMDTC Group
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing